Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

KNTE Financial Statements and Analysis

NASDAQ : KNTE

Kinnate Biopharma Inc.

$2.65
-0.01-0.38%
At Close 4:00 PM
Not Actively Trading
59.62
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateDec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202320232022
periodQ4Q3Q2Q1Q4
revenue00000
cost of revenue198.00K197.00K201.00K203.00K0
gross profit-198.00K-197.00K-201.00K-203.00K0
gross profit ratio00000
research and development expenses13.37M24.511M26.327M26.559M25.188M
general and administrative expenses5.734M6.605M7.808M8.094M7.496M
selling and marketing expenses-198.00K0000
selling general and administrative expenses5.536M6.605M7.808M8.094M7.496M
other expenses2.241M1.973M2.217M1.713M1.121M
operating expenses18.906M33.089M34.135M34.653M32.684M
cost and expenses19.104M33.089M34.135M34.653M32.684M
interest income2.241M0000
interest expense000-1.713M494.00K
depreciation and amortization198.00K197.00K201.00K203.00K190.00K
ebitda-18.906M-33.089M-33.934M-34.653M-32.494M
ebitda ratio00000
operating income-19.104M-33.089M-34.135M-34.653M-32.684M
operating income ratio00000
total other income expenses net2.046M2.356M2.217M1.713M1.121M
income before tax-17.058M-30.733M-31.918M-32.94M-31.563M
income before tax ratio00000
income tax expense0-197.00K0-1.713M-1.615M
net income-17.058M-30.733M-31.918M-31.227M-29.948M
net income ratio00000
eps-0.36-0.65-0.68-0.69-0.68
eps diluted-0.36-0.65-0.68-0.69-0.68
weighted average shs out47.124M47.095M46.656M45.41M44.066M
weighted average shs out dil47.124M47.095M46.656M45.41M44.066M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateDec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202320232022
periodQ4Q3Q2Q1Q4
cash and cash equivalents56.998M51.662M34.507M73.57M29.261M
short term investments97.036M115.914M150.196M127.411M172.214M
cash and short term investments154.034M167.576M184.703M200.981M201.475M
net receivables00000
inventory00000
other current assets4.143M2.725M3.897M4.307M3.637M
total current assets158.177M170.301M188.60M205.288M230.837M
property plant equipment net4.76M5.13M5.625M6.047M6.448M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments10.63M12.762M19.579M30.203M39.139M
tax assets00000
other non current assets37.999K2.516M2.331M2.342M2.402M
total non current assets15.428M20.408M27.535M38.592M47.989M
other assets1.000000
total assets173.605M190.709M216.135M243.88M278.826M
account payables2.031M2.929M2.696M4.451M2.97M
short term debt892.00K869.00K959.00K983.00K991.00K
tax payables00000
deferred revenue00000
other current liabilities9.072M11.976M12.118M12.721M13.206M
total current liabilities11.995M15.774M15.773M18.155M17.167M
long term debt2.283M2.515M2.742M2.963M3.191M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities00000
total non current liabilities2.283M2.515M2.742M2.963M3.191M
other liabilities00000
capital lease obligations2.283M3.384M3.701M3.946M4.182M
total liabilities14.278M18.289M18.515M21.118M20.358M
preferred stock00000
common stock5.00K5.00K5.00K5.00K4.00K
retained earnings-372.012M-354.954M-324.221M-292.303M-259.363M
accumulated other comprehensive income loss-12.00K-147.00K-342.00K-464.00K-1.41M
other total stockholders equity531.346M527.516M522.178M515.524M484.237M
total stockholders equity159.327M172.42M197.62M222.762M223.468M
total equity159.327M172.42M197.62M222.762M223.468M
total liabilities and stockholders equity173.605M190.709M216.135M243.88M278.826M
minority interest000035.00M
total investments107.666M128.676M169.775M157.614M211.353M
total debt3.175M3.384M3.701M3.946M4.182M
net debt-53.823M-48.278M-30.806M-69.624M-25.079M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateDec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202320232022
periodQ4Q3Q2Q1Q4
deferred income tax-8.028M3.942M3.743M00
stock based compensation3.83M5.281M5.403M5.404M4.942M
change in working capital-3.15M1.059M-1.97M357.00K2.973M
accounts receivables00000
inventory00000
accounts payables-3.802M91.00K-2.358M996.00K4.195M
other working capital652.00K968.00K388.00K-639.00K-1.222M
other non cash items6.843M-5.281M-4.882M-744.00K-290.00K
net cash provided by operating activities-17.365M-25.535M-29.423M-27.72M-23.748M
investments in property plant and equipment009.00K-9.00K-90.00K
acquisitions net-9.133M010.893K-55.429K0
purchases of investments-19.154M-29.319M-73.149M-33.097M-45.446M
sales maturities of investments41.854M71.952M62.256M88.526M63.103M
other investing activites00-10.893K55.429K0
net cash used for investing activites13.567M42.633M-10.884M55.42M17.567M
debt repayment00000
common stock issued057.00K1.251M17.00K945.00K
common stock repurchased0000621.00K
dividends paid00000
other financing activites9.133M01.251K-9.133M-1.373M
net cash used provided by financing activities9.133M57.00K1.251M-9.116M193.00K
effect of forex changes on cash1.00K-11.874M43.938M03.00K
net change in cash5.336M17.155M-39.063M18.584M-5.985M
cash at end of period56.998M52.033M34.878M73.941M55.357M
cash at beginning of period51.662M34.878M73.941M55.357M61.342M
operating cashflow-17.365M-25.535M-29.423M-27.72M-23.748M
capital expenditure009.00K-9.00K-90.00K
free cash flow-17.365M-25.535M-29.414M-27.729M-23.838M
Graph

Frequently Asked Questions

How did Kinnate Biopharma Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, KNTE generated $0.00 in revenue last quarter, while its costs came in at $198.00K.
Last quarter, how much Gross Profit did Kinnate Biopharma Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Kinnate Biopharma Inc. reported a -$198.00K Gross Profit for the quarter ended Dec 31, 2023.
Have KNTE's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. KNTE incurred $18.91M worth of Operating Expenses, while it generated -$19.10M worth of Operating Income.
How much Net Income has KNTE posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Kinnate Biopharma Inc., the company generated -$17.06M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Kinnate Biopharma Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Kinnate Biopharma Inc. as of the end of the last quarter was $57.00M.
What are KNTE's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, KNTE had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Kinnate Biopharma Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of KNTE were $158.18M, while the Total Assets stand at $173.61M.
As of the last quarter, how much Total Debt did Kinnate Biopharma Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of KNTE's debt was $3.18M at the end of the last quarter.
What were KNTE's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, KNTE reported total liabilities of $14.28M.
How much did KNTE's Working Capital change over the last quarter?
Working Capital Change for KNTE was -$3.15M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
KNTE generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. KNTE generated -$17.37M of Cash from Operating Activities during its recently reported quarter.
What was KNTE's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. KNTE reported a $5.34M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph